| Joel Mason, MD | |
|
750 Washington St, Nemc Box 836, Boston, MA 02111-1526 | |
| (617) 636-5000 | |
| Not Available |
| Full Name | Joel Mason |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 43 Years |
| Location | 750 Washington St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164539292 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 57484 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tufts Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pratt Medical Group Inc | 3375515661 | 265 |
News Archive
Kaiser Health News: Two advocate groups say hospitals make it too difficult for patients to find out whether they are eligible for free or discounted care. Access Project and Community Catalyst, the two groups, released the results of a small, 99-hospital survey Wednesday. The American Hospital Association contends that's too small to be meaningful, and that, at any rate, the issues it raises have been addressed in the health overhaul.
Tau PET is a new and promising imaging method for Alzheimer's disease. A case study from Lund University in Sweden now confirms that tau PET images correspond to a higher degree to actual changes in the brain. According to the researchers behind the study, this increases opportunities for developing effective drugs.
A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients' cells can be clinically useful in patients with aggressive hematological cancers.
National Institutes of Health (NIH) Director Francis Collins on Tuesday announced the agency is moving forward on plans to create a new research center focused on translational science, after NIH's advisory board voted to create the new center, Science's "Science Insider" blog reports (Kaiser, 12/7).
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
› Verified 1 days ago
| Entity Name | Pratt Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275570319 PECOS PAC ID: 3375515661 Enrollment ID: O20040807000255 |
News Archive
Kaiser Health News: Two advocate groups say hospitals make it too difficult for patients to find out whether they are eligible for free or discounted care. Access Project and Community Catalyst, the two groups, released the results of a small, 99-hospital survey Wednesday. The American Hospital Association contends that's too small to be meaningful, and that, at any rate, the issues it raises have been addressed in the health overhaul.
Tau PET is a new and promising imaging method for Alzheimer's disease. A case study from Lund University in Sweden now confirms that tau PET images correspond to a higher degree to actual changes in the brain. According to the researchers behind the study, this increases opportunities for developing effective drugs.
A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients' cells can be clinically useful in patients with aggressive hematological cancers.
National Institutes of Health (NIH) Director Francis Collins on Tuesday announced the agency is moving forward on plans to create a new research center focused on translational science, after NIH's advisory board voted to create the new center, Science's "Science Insider" blog reports (Kaiser, 12/7).
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joel Mason, MD 750 Washington St, Nemc Box 836, Boston, MA 02111-1526 Ph: (617) 636-7105 | Joel Mason, MD 750 Washington St, Nemc Box 836, Boston, MA 02111-1526 Ph: (617) 636-5000 |
News Archive
Kaiser Health News: Two advocate groups say hospitals make it too difficult for patients to find out whether they are eligible for free or discounted care. Access Project and Community Catalyst, the two groups, released the results of a small, 99-hospital survey Wednesday. The American Hospital Association contends that's too small to be meaningful, and that, at any rate, the issues it raises have been addressed in the health overhaul.
Tau PET is a new and promising imaging method for Alzheimer's disease. A case study from Lund University in Sweden now confirms that tau PET images correspond to a higher degree to actual changes in the brain. According to the researchers behind the study, this increases opportunities for developing effective drugs.
A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients' cells can be clinically useful in patients with aggressive hematological cancers.
National Institutes of Health (NIH) Director Francis Collins on Tuesday announced the agency is moving forward on plans to create a new research center focused on translational science, after NIH's advisory board voted to create the new center, Science's "Science Insider" blog reports (Kaiser, 12/7).
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
› Verified 1 days ago
Kaitlyn My-tu Lam, MBBS Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |